Redeye: AlzeCure Pharma (Q1 Review): Advancing toward Phase IIa with NeuroRestore ACD856
Redeye’s analyst just published a Research Update on AlzeCure Pharma.
Click here to read the article
Make sure to add AlzeCure Pharma to your Watchlist at Redeye and our analysts will notify you if anything relevant happens regarding your companies.
This is a press release from Redeye - Nordic Growth. www.redeye.se